2008	2009	2010	2011	2012	2013	2014	2015	2016	2017
	BRAVO
	0	0	0	0	0	0	1	1	0	0
	A REAL ADVANCE
	0	0	1	0	1	0	2	3	1	1 (b)
	OFFERS AN ADVANTAGE
	6	3	3	3	3	6	5	5	5	9 (c)
	POSSIBLY HELPFUL
	25	14	22	13	14	12	15	15	9	18
	NOTHING NEW
	57	62	49	53	42	48	35	43	56	45
	NOT ACCEPTABLE
	23	19	19	16	15	15	19	15	15	15 (d)
	JUDGEMENT RESERVED
	9	6	3	7	7	9	10	6	5	4 (e)
TOTAL	120	104	97	92	82	90	87	87	92	92
See: the year in review	2008 (pdf)	2009 (pdf)	2010 (pdf)	2011 (pdf)	2012 (pdf)	2013 (pdf)	2014 (pdf)	2015 (pdf)	2016 (pdf)	2017 (pdf)
For details on these categories, see: > Prescrire's drug ratings

a- About this table

This table includes new products (except generics) and new indications as well as our updated reviews (A second look).

b- The only drug rated "A REAL ADVANCE" in 2017 was:

• Asfotase alfa in hypophosphatasia (Prescrire Int n° 187).

c- The drugs rated "OFFERS AN ADVANTAGE" in 2017 were:

• emtricitabine + tenofovir disoproxil in the prevention of HIV transmission (Prescrire Int n° 187);
• eribulin in inoperable refractory or relapsed liposarcoma (Prescrire Int n° 187);
• methotrexate SC in prefilled pens (Rev Prescrire n° 404);
• methotrexate injection in ectopic pregnancies (Prescrire Int n° 190);
• oral nitisinone in type 1 tyrosinemia (Rev Prescrire n° 410);
• nivolumab in metastatic renal cancers, in 2nd line after failure of a tyrosine kinase inhibitor (Prescrire Int n° 185);
• pertuzumab in metastatic breast cancer (Prescrire Int n° 184);
• raltegravir granules for oral suspension in infants infected with HIV (Prescrire Int n° 185);
• sofosbuvir + velpatasvir in hepatitis C (Prescrire Int n° 192).

d- The drugs rated "NOT ACCEPTABLE" in 2017 were:

• adalimumab in hidradenitis suppurative in adolescents (Prescrire Int n° 181);
• ataluren in Duchenne muscular dystrophy (Prescrire Int n° 189);
• bevacizumab 1st line in lung cancers (Prescrire Int n° 188);
• brentuximab vedotin in Hodgkin lymphoma (Prescrire Int n° 191);
• equine estrogens + bazedoxifene in menopausal symptoms (Prescrire Int n° 184);
• everolimus in non functioning neuroendocrine tumours (Rev Prescrire n° 405);
• fentanyl iontophoretic in pain (Rev Prescrire n° 409);
• guanfacine for attention deficit with hyperactivity (Prescrire Int n° 186);
• nivolumab in Hodgkin lymphoma after failure of an autologous stem cell transplant and brentuximab vedotin (Prescrire Int n° 191);
• palbociclib in inoperable or metastatic breast cancers (Rev Prescrire n° 410);
• pertuzumab before breast cancer surgery (Prescrire Int n° 184);
• reslizumab in asthma (Rev Prescrire n° 410);
• selexipag in pulmonary arterial hypertension (Prescrire Int n° 186);
• tolvaptan in autosomal dominant polycystic kidney disease (Prescrire Int n° 187);
• vandetanib in medullary thyroid cancer in children (Rev Prescrire n° 408).

e- The drugs rated "JUDGEMENT RESERVED" in 2017 were:

• ivacaftor in cystic fibrosis (Prescrire Int n° 188);
• ivacaftor + lumacaftor in cystic fibrosis (Prescrire Int n° 188);
• pembrolizumab monotherapy in metastatic or inoperable lung cancers (Rev Prescrire n° 407);
• teduglutide in short bowel syndrome in children (Rev Prescrire n° 404).

 

©Prescrire 1 April 2018

"Drugs in 2017: a brief review" Prescrire Int 2018; 27 (192): 110-111. (Pdf, free)